[
    {
        "query": "\n                Analyze the provided CSV file and generate a detailed description of each row by extracting and summarizing its features in a continuous sentence. For each row:\n\n                1. Identify and list the column names and their corresponding values.\n                2. Present the features in the row in a seamless sentence structure, describing the relationship or context between them.\n                3. Provide a summary statement based on the data, capturing notable insights, patterns, or potential interpretations.\n                ",
        "response": "Here's an analysis of the provided data, presented as requested:\n\n**Row 108:**  This row contains the drug Potassium Acetate, identified by RXCUI 54987, with drug labels listing \"POTASSIUM ACETATE\" and \"POTASSIUM ACETATE.\"  No indications are listed in the provided fields.  Summary:  The data describes Potassium Acetate but lacks information regarding its clinical indications.\n\n\n**Row 106:** This row details Thalidomide (RXCUI 10432), also known as Thalomid, indicated for a wide range of conditions including plasma cell myeloma, myelofibrosis, and various other cancers and inflammatory diseases, as listed by label, MONDO ontology terms, and UMLS CUI codes. Summary: Thalidomide has a broad range of indicated uses, spanning multiple disease categories and represented across various ontologies.\n\n\n**Row 107:** This row represents Alunbrig (Brigatinib, RXCUI 1921217), indicated for malignant lung neoplasms, as shown in the label, MONDO:0008903, and UMLS C0242379. Summary: Alunbrig is specifically indicated for the treatment of malignant lung tumors.\n\n\n**Row 105:** This row describes Eptifibatide (Integralin, RXCUI 75635), indicated for thrombosis and cerebral artery occlusion, supported by label, MONDO terms (MONDO:0000831 and MONDO:0000944), and UMLS codes (C0040053 and C0028790). Summary: Eptifibatide is used to treat blood clot related conditions, specifically thrombosis and cerebral artery occlusion.\n\n\n**Row 109:** This row contains information on Dalbavancin (Dalvance, RXCUI 1539239), indicated for cellulitis, as shown by label, MONDO:0005230, and UMLS C0007642. Summary: Dalbavancin is an antibiotic indicated for the treatment of cellulitis."
    }
]